NorthCrest Asset Manangement LLC Raises Stock Position in United Therapeutics Co. (NASDAQ:UTHR)

NorthCrest Asset Manangement LLC boosted its holdings in shares of United Therapeutics Co. (NASDAQ:UTHR) by 4.5% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 5,514 shares of the biotechnology company’s stock after purchasing an additional 238 shares during the period. NorthCrest Asset Manangement LLC’s holdings in United Therapeutics were worth $1,976,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds also recently added to or reduced their stakes in UTHR. Forsta AP Fonden boosted its stake in shares of United Therapeutics by 10.8% in the third quarter. Forsta AP Fonden now owns 8,200 shares of the biotechnology company’s stock worth $2,938,000 after buying an additional 800 shares during the last quarter. Mediolanum International Funds Ltd boosted its position in United Therapeutics by 6.9% in the 3rd quarter. Mediolanum International Funds Ltd now owns 4,804 shares of the biotechnology company’s stock worth $1,720,000 after purchasing an additional 312 shares in the last quarter. Values First Advisors Inc. acquired a new stake in shares of United Therapeutics during the 3rd quarter worth approximately $90,000. Impact Partnership Wealth LLC purchased a new position in shares of United Therapeutics during the 3rd quarter valued at approximately $254,000. Finally, Hennion & Walsh Asset Management Inc. lifted its stake in shares of United Therapeutics by 31.4% in the 3rd quarter. Hennion & Walsh Asset Management Inc. now owns 4,286 shares of the biotechnology company’s stock valued at $1,536,000 after purchasing an additional 1,023 shares during the period. 94.08% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other United Therapeutics news, COO Michael Benkowitz sold 25,000 shares of United Therapeutics stock in a transaction dated Wednesday, August 7th. The stock was sold at an average price of $323.38, for a total transaction of $8,084,500.00. Following the completion of the sale, the chief operating officer now directly owns 2,577 shares of the company’s stock, valued at $833,350.26. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. In other news, COO Michael Benkowitz sold 25,000 shares of the firm’s stock in a transaction dated Wednesday, August 7th. The stock was sold at an average price of $323.38, for a total transaction of $8,084,500.00. Following the sale, the chief operating officer now owns 2,577 shares of the company’s stock, valued at approximately $833,350.26. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO James Edgemond sold 7,782 shares of the company’s stock in a transaction that occurred on Monday, October 21st. The shares were sold at an average price of $366.99, for a total value of $2,855,916.18. Following the completion of the transaction, the chief financial officer now directly owns 6,426 shares of the company’s stock, valued at $2,358,277.74. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 102,812 shares of company stock worth $35,251,926. Corporate insiders own 12.50% of the company’s stock.

Analysts Set New Price Targets

UTHR has been the topic of several analyst reports. Oppenheimer raised their price target on shares of United Therapeutics from $400.00 to $575.00 and gave the company an “outperform” rating in a research report on Wednesday, August 28th. Bank of America reduced their price target on United Therapeutics from $303.00 to $280.00 and set an “underperform” rating for the company in a report on Thursday, August 1st. UBS Group raised their price objective on United Therapeutics from $300.00 to $370.00 and gave the company a “buy” rating in a report on Monday, July 8th. Morgan Stanley cut United Therapeutics from an “overweight” rating to an “equal weight” rating and boosted their price objective for the company from $310.00 to $321.00 in a research report on Thursday, July 11th. Finally, TD Cowen increased their target price on United Therapeutics from $350.00 to $400.00 and gave the company a “buy” rating in a research report on Monday, October 21st. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating, ten have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $361.33.

United Therapeutics Price Performance

UTHR stock opened at $348.65 on Friday. United Therapeutics Co. has a 1 year low of $208.62 and a 1 year high of $377.03. The firm has a market capitalization of $15.46 billion, a P/E ratio of 16.48, a P/E/G ratio of 1.35 and a beta of 0.57. The company has a debt-to-equity ratio of 0.02, a current ratio of 4.35 and a quick ratio of 4.18. The business’s 50-day moving average is $354.00 and its two-hundred day moving average is $312.79.

United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings results on Wednesday, July 31st. The biotechnology company reported $5.85 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $6.33 by ($0.48). United Therapeutics had a return on equity of 18.82% and a net margin of 40.87%. The firm had revenue of $714.90 million during the quarter, compared to analysts’ expectations of $691.87 million. During the same quarter in the prior year, the firm earned $5.24 EPS. The firm’s revenue was up 19.8% compared to the same quarter last year. Analysts anticipate that United Therapeutics Co. will post 24.72 earnings per share for the current fiscal year.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.